and diagnostics executive at SmithKline Setting up a combinatorial chemistry the simultaneous administration of
Beecham and Gen Trak, as Vice department, a task that Moos is greatly forskolin, an adenylate cyclase activator,
President, and her initial task will be to experienced in, is not on the cards at the and milrinbne, an inhibitor of type III
bring the first blood-based diagnostic moment. Bob Davis and he think that cyclic nucleotide phosphodiesterase (a
test for Alzheimer’s disease to the mar- there are already too many good players combination found to give a maximum
ket. Moos hopes that MitoKor’s diagnos- in that field: ‘If someone is already doing rise in intracellular CAMP), leads to chlo-
tics operation will be a $150 million dol- it, and doing it well, there is no sense for ride transport through the mutated CFI’R
lar business in Alzheimer’s alone. MitoKor to do it. We are only going channel protein in nasal epithelial cells
Diagnostics will also give MitoKor the to do the things we can have a competi- of a mouse CF model. However, admin-
opportunity to support a managed care tive advantage in. If we can’t have a istration of either compound alone was
environment. The diagnostic tests will competitive advantage, we’ll do it with a completely in
update开题资料开题资料 来自淘豆网www.taodocs.com转载请标明出处.